Abstract
Cancer is the result of uncontrolled cell proliferation and has emerged as one of the most frequently diagnosed challenges to human health all over the world. While formation of new cells is an integral part of cancer biology, decreased death of tumor cells has recently emerged as a focus of attention as the leading cause of deregulated tissue homeostasis resulting in cancer-related tumor burden. The cell loss factor is the major determinant of tumor growth rate with values approaching to as high as 90% in some case (1). Chemotherapeutic drugs are designed to reverse the order of cancer cell behavior by blocking cell division and/or increasing cell death. Apoptosis, or programmed cell death, is a genetically based suicide mechanism preserved through evolutionary ages (2), by which infected and damaged cells are selectively eliminated from the body in a controlled fashion without much inflammatory or bystander effects. It is the dominant mechanism of cell death in multicellular species. Drugs currently in use for cancer chemotherapy, in most cases, work by induction of apoptosis, either through membrane-localized cell death receptor-mediated signals or by the involvement of mitochondria. Other cancer-therapeutic modalities including radiotherapy, immunotherapy and hormone ablation also induce cell death by apoptosis. Tumor cells, on the other hand, are posing a threat of drug-resistance by deregulating the cell-death program (“drug neo-resistance”) or immuno-resistance by expressing cell death signal-inducing ligands on their surface to counterattack the antitumor lymphocytes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
tSteel, G. G. (1977) In Growth Kinetics of Tumors, Oxford University Press, Oxford.
Steller, H. Mechanisms and genes of cellular suicide. Science (Washington DC), 267:1445–1449 (1995).
Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer Statistics, 1997.CA Cancer J. Clin.47:5–27 (1997).
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, A., Blumenstein,B. A., Davis, M. A., and Goodman, P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.N. Eng. J. Med.321:419–424 (1989).
Ghosh, J., and Myers, C. EArachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase.Biochem. Biophys. Res. Commun.235:418–423 (1997).
Whittemore, A. S., Kolonel, L. N., Wu, A. H., John, E. M., Gallagher, R. P., Howe, G. W., Burch, J. D.,Hankin, J., Dreon, D. M., West, D. W., Teh, C., and Paffenbarger, R. S. Prostate cancer in relation to diet, physical activity and body size, in blacks, whites and asians in the U. S. and Canada.J. Natl. Cancer Inst.87:652–661 (1995).
Mettlin, C., Selenskas, S., Natarajan, N., and Huben, R. Beta-carotene and animal fats and their relationship to prostate cancer risk.Cancer64:605–612 (1989).
Giovannucci, E., Rimm, E. B., Colditz, G. A., Stampfer, M. J., Ascherio, A., Chute, C. C., and Willett, W. C. A prospective study of dietary fat and risk of prostate cancer.J. Natl. Cancer Inst.85:1571–1579 (1993).
Le Marchand, L., Kolonel, L. N., Wilkins, L. R., Myers, B. C., and Hirohata, T. Animal fat consumption and cancer of the prostate: a prospective study in Howaii.Epidemiology5:276–282 (1994).
Gann, P. H., Hennekens, C. H., Sacks, F. M., Grodstein, F., Giovannucci, E., and Stampfer, M. J. Prospective study of plasma fatty acids and risk of prostate cancer.J. Natl. Cancer Inst.86:281–286 (1994).
Wang, Y., Corr, J. G., Thaler, H. T., Tao, Y., Fair, W. R., and Heston, W. D. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet.J. Natl. Cancer Inst.87:1456–1462 (1995).
Han, J., McCormick, F., and Macara, I. G. Regulation of Ras-GAP and the neurofibromatosis-1 gene product by eicosanoids.Science(Washington DC) 252:576–579 (1991).
Khan, W. A., Blobe, G. C., and Hannun, Y. A. Arachidonic acid and free fatty acids as second messengers and the role of protein kinase C.Cell. Signaling7:171–184 (1995).
Schachter, J. B., Lester, D. S., and Alkon, D. L. Synergistic activation of protein kinase C by arachidonic acid and diacylglycerol in vitro: generation of a stable membrane—bound, cofactor-independent state of protein kinase C activity.Biochim. Biophys. Acta1291:167–176 (1996).
Ara,G., and Teicher, B. A. Cyclooxygenase and lipoxygenase inhibitors in cancer therapy.Prostaglandins Leukotrienes and Essential Fatty Acids 54:3–16 (1996).
Young, M. R. Eicosanoids and the immunology of cancer.Cancer Met. Rev.13: 337–348 (1994).
Lim, H., Paria, B. C., Das, S. K., Dinchuk, J. E., Langenbach, R., Trzaskos, J. M., and Dey, S. K. Multiple female reproductive failures in cyclooxygenase 2-deficient mice.Cell91:197–208 (1997).
Goetzl, E. J., An, S., and Zheng, L. Specific suppression by prostaglandin E2 of activation-induced apoptosis of human CD4’8’T lymphoblasts.J. Immunol.154:1041–1047 (1995).
Ghosh, J., and Myers, C. E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells.Proc. Natl. Acad. Sci. USA95:13182 3187 (1998).
Ghosh, J., and Myers, C. E. Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells.Adv. Exp. Med. Biol.469:577–582 (1999).
Rokhlin, O. W., Bishop, G. A., Hostager, B. S., Waldschmidt, T. J., Sidorenko, S. P., Pavloff, N., Kiefer, M. C., Umansky, S. R., Glover, R. A., and Cohen, M. B. Fas-mediated apoptosis in human prostatic carcinoma cell lines.Cancer Res.57:1758–1768 (1997).
Hedlund, T. E., Duke, R. C., Schleicher, M. S., and Miller, G. J. Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage.Prostate36:92–101 (1998).
Frost, P. J., Ng, C. P., Belldegrun, A., and Bonavida, B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-FasL pathway of cytotoxicity.Cell. Immunol.180:70–83 (1997).
Uslu, R., Borsellino, N., Frost, P. J., Garban, H., Ng, C. P., Mizutani, Y., Belldegrun, A., and Bonavida, B. Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis.Clin. Cancer Res.3:963–972 (1997).
Liu, Q. Y., Rubin, M. A., Omene, C., Lederman, S., and Stein, C. A. Fas ligand is constitutively secreted by prostate cancer cells in vitro.Clin. Cancer Res.4:1803–1811 (1998).
Chinnaiyan, A. M. The apoptosome: heart and soul of the cell death machine.Neoplasia1:5–15 (1999).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ghosh, J., Myers, C.E. (2002). Molecular Mechanisms of Prostate Cancer Cell Death Triggered by Inhibition of Arachidonate 5-Lipoxygenase: Involvement of Fas Death Receptor-Mediated Signals. In: Honn, K.V., Marnett, L.J., Nigam, S., Dennis, E., Serhan, C. (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 5. Advances in Experimental Medicine and Biology, vol 507. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0193-0_64
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0193-0_64
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4960-0
Online ISBN: 978-1-4615-0193-0
eBook Packages: Springer Book Archive